All In MedTech

Device Trial Radar · NCT06411418

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Actual

Start

Sep 1, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Jacobs instituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 13, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms

Conditions

  • Intracranial Aneurysms

Interventions

  • Pipeline™ Flex Embolization Device with Shield Technology™Device

    The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of thromboembolic event(s)Time frame: 60 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University at Buffalo Neurosurgery

    Buffalo, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.